How UCB beat 2 oth­er bid­ders to land $1.9B buy­out of Zo­genix and its epilep­sy drug

Days be­fore it would nail down the FDA’s ap­proval for its epilep­sy drug Fin­tepla, Zo­genix re­ceived one of the first in­quiries from a phar­ma com­pa­ny about pur­su­ing a po­ten­tial part­ner­ship to mar­ket the drug in the EU and oth­er ge­o­gra­phies out­side the US.

But it wasn’t un­til the OK came through, in late June, that even­tu­al buy­er UCB made ini­tial con­tact, ac­cord­ing to an SEC fil­ing de­tail­ing the back­ground lead­ing up to the deal.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN